Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Uncategorized

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $129

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.
byBenzinga Newsdesk
May 3, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Analyzing Rayonier’s Ex-Dividend Date

By Benzinga Insights
Today, 7:41 AM
On May 24, 2021, Rayonier (NYSE:RYN) declared a dividend payable on June 30, 2021 to its shareholders. Rayonier also announced that shareholders on the company's books on or before June 16, 2021 are entitled to the dividend. The stock will then go ex-dividend 1 business day(s) before the record date.

RYN